Abstract
Cerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event and this risk is magnified in younger individuals and in patients with hypertension and complications in other vascular beds. In addition, when patients with diabetes and hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the one FDA-approved therapy, intravenous tissue plasminogen activator. Experimental stroke models have revealed that chronic hyperglycemia leads to deficits in cerebrovascular structure and function that may explain some of the clinical observations. Increased edema, neovascularization and protease expression as well as altered vascular reactivity and tone may be involved and point to potential therapeutic targets. Further study is needed to fully understand this complex disease state and the breadth of its manifestation in the cerebrovasculature.
Keywords: Cerebral vasculature, diabetes, hemorrhage, ischemia, stroke, targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Cerebrovascular Complications of Diabetes: Focus on Stroke
Volume: 12 Issue: 2
Author(s): Adviye Ergul, Aisha Kelly-Cobbs, Maha Abdalla and Susan C. Fagan
Affiliation:
Keywords: Cerebral vasculature, diabetes, hemorrhage, ischemia, stroke, targets
Abstract: Cerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event and this risk is magnified in younger individuals and in patients with hypertension and complications in other vascular beds. In addition, when patients with diabetes and hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the one FDA-approved therapy, intravenous tissue plasminogen activator. Experimental stroke models have revealed that chronic hyperglycemia leads to deficits in cerebrovascular structure and function that may explain some of the clinical observations. Increased edema, neovascularization and protease expression as well as altered vascular reactivity and tone may be involved and point to potential therapeutic targets. Further study is needed to fully understand this complex disease state and the breadth of its manifestation in the cerebrovasculature.
Export Options
About this article
Cite this article as:
Ergul Adviye, Kelly-Cobbs Aisha, Abdalla Maha and C. Fagan Susan, Cerebrovascular Complications of Diabetes: Focus on Stroke, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (2) . https://dx.doi.org/10.2174/187153012800493477
DOI https://dx.doi.org/10.2174/187153012800493477 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme
Current Medicinal Chemistry Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome
Current Vascular Pharmacology Lipid Raft in Cardiac Health and Disease
Current Cardiology Reviews Prevalence, Correlates and Management of Hyperglycemia in Diabetic Non-critically Ill Patients at a Tertiary Care Center in Lebanon
Current Diabetes Reviews Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Current Pharmaceutical Design Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy
Current Drug Targets 1h Post-load Blood Glucose in the Identification of Proatherogenic Cardiometabolic Profile in Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Effect of Simvastatin use on Autonomic Function in Patients with End Stage Renal Disease
Cardiovascular & Hematological Disorders-Drug Targets Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors
Current Neurovascular Research The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Mesenchymal Stem Cells: A Potent Cell Source for COVID-19
Coronaviruses Selected Herbals for Sports Injuries
The Natural Products Journal Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Leptin in Non-Autoimmune Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Diabetes and Gestational Hypertension
Current Hypertension Reviews